1. Legal requirement: Guideline for the notification of serious breaches of Regulation (EU) No 536/2014 or the clinical trial protocol

Management of serious breaches of clinical trials authorised in the Europe Union (EU)/ European Economic Area (EEA) is defined by Regulation (EU) No 536/2014, which states in Article 52:

“1. The sponsor shall notify the Member States concerned about a serious breach of this Regulation or of the version of the protocol applicable at the time of the breach through the EU portal without undue delay but not later than seven days of becoming aware of that breach.

2. For the purposes of this Article, a ‘serious breach’ means a breach likely to affect to a significant degree the safety and rights of a subject or the reliability and robustness of the data generated in the clinical trial.”

 

© European Medicines Agency, 2021

Clinical Research News

Upcoming Clinical Research Training and Conferences

Upcoming Clinical Trials

Subscribe
3